OHSU

IRB #

IRB00009174

Title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (Odyssey Outcomes)

Principal Investigator

Michael Shapiro

Study Purpose

The purpose of this study is to learn more about a study drug that may help prevent future cardiovascular events (such as heart attack or stroke). The study drug may help reduce LDL (bad) cholesterol.

Medical Condition(s)

Acute coronary syndrome (ACS)
High cholesterol
Ccardiovascular

Eligibility Criteria

Includes but not limited to:
-Men and women age 18+
-Subjects with high cholesterol who experienced acute coronary syndrome (ACS) in the last 12 months.
-Subjects also at risk to experience another cardiovascular event (such as heart attack or stroke) in the future.

Age Range

40 - 99

Healthy Volunteers Needed

No

Duration of Participation

2-5 years

Minors Included

No

Contact

Rebecca Boucher, RN
Study Coordinator
(503) 494-2927

Sponsor

Sanofi US

Recruitment End

01/29/2016

Compensation Provided

Yes

Compensation

To reimburse for time and travel, subjects will be paid $100.00 for each study visit to OHSU.


Go Back